1fko: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1fko.gif|left|200px]]
{{Seed}}
[[Image:1fko.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1fko|  PDB=1fko  |  SCENE=  }}  
{{STRUCTURE_1fko|  PDB=1fko  |  SCENE=  }}  


'''CRYSTAL STRUCTURE OF NNRTI RESISTANT K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DMP-266(EFAVIRENZ)'''
===CRYSTAL STRUCTURE OF NNRTI RESISTANT K103N MUTANT HIV-1 REVERSE TRANSCRIPTASE IN COMPLEX WITH DMP-266(EFAVIRENZ)===




==Overview==
<!--  
BACKGROUND: Efavirenz is a second-generation non-nucleoside inhibitor of HIV-1 reverse transcriptase (RT) that has recently been approved for use against HIV-1 infection. Compared with first-generation drugs such as nevirapine, efavirenz shows greater resilience to drug resistance mutations within HIV-1 RT. In order to understand the basis for this resilience at the molecular level and to help the design of further-improved anti-AIDS drugs, we have determined crystal structures of efavirenz and nevirapine with wild-type RT and the clinically important K103N mutant. RESULTS: The relatively compact efavirenz molecule binds, as expected, within the non-nucleoside inhibitor binding pocket of RT. There are significant rearrangements of the drug binding site within the mutant RT compared with the wild-type enzyme. These changes, which lead to the repositioning of the inhibitor, are not seen in the interaction with the first-generation drug nevirapine. CONCLUSIONS: The repositioning of efavirenz within the drug binding pocket of the mutant RT, together with conformational rearrangements in the protein, could represent a general mechanism whereby certain second-generation non-nucleoside inhibitors are able to reduce the effect of drug-resistance mutations on binding potency.
The line below this paragraph, {{ABSTRACT_PUBMED_11080630}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 11080630 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_11080630}}


==About this Structure==
==About this Structure==
Line 36: Line 40:
[[Category: Hiv-1 reverse transcriptase]]
[[Category: Hiv-1 reverse transcriptase]]
[[Category: Non-nucleoside inhibitor]]
[[Category: Non-nucleoside inhibitor]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 16:26:21 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 1 03:24:35 2008''